Tralokinumab real-world use in adults with atopic dermatitis: baseline characteristics of the first 100 patients recruited to the TRACE Study in the United States

April W. Armstrong1, Cory Rubin2, Abel Jarell3, Tien Nguyen4, Jerry Bagel5, John Stinson6, Shannon Schneider7, Dimitra M. Anastasiadou6, Adrian Rodriguez8

1University of California Los Angeles, Los Angeles, CA, USA; 2Michigan Dermatology Institute, Waterford, MI, USA; 3Northeast Dermatology Associates, Portsmouth, NH, USA; 4First OC Dermatology, Fountain Valley, CA, USA

Purpose
To report the baseline characteristics of the first 100 patients enrolled in the Tralokinumab Real-World Use in Adults with Atopic Dermatitis (TRACE) Study in the United States.

Methods
• TRACE is a global, observational, prospective, single-arm study of tralokinumab-treated patients with moderate-to-severe AD, designed to assess changes in clinical signs and symptoms of patients in a real-world setting.

Baseline disease severity and quality of life

<table>
<thead>
<tr>
<th>Measure</th>
<th>Biologic-naïvea</th>
<th>Total</th>
<th>Biologic-experiencedb</th>
<th>Total</th>
<th>Differences (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>SCORAD</td>
<td>14.1 (13.0–15.1)</td>
<td>14.4 (13.0–15.2)</td>
<td>1.3 (−1.0 to 3.6)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EASI</td>
<td>15.4 (7.9)</td>
<td>15.4 (7.9)</td>
<td>0.0 (−6.6 to 6.6)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DLQI</td>
<td>19.3 (14.6)</td>
<td>19.5 (14.6)</td>
<td>0.2 (−1.4 to 1.8)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PSS</td>
<td>4.2 (3.3)</td>
<td>4.2 (3.3)</td>
<td>0.0 (−1.3 to 1.3)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Conclusions
• Initial findings showed that tralokinumab is being used as a first-line biologic treatment in the US, in accordance with the label.
• Biologic-experienced patients were on average older with a longer disease duration, and a higher proportion had comorbidities compared with biologic-naïve patients.
• Treated patients had a heavy burden of disease with considerable impact on quality of life.

References

2. Jensen for assistance with the statistical analyses. This work was previously presented at the 2023 Fall Clinical Dermatology Conference.

Disclosures

No potential conflict of interest relevant to this article was reported.